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THE PREVALENCE AND SEVERITY OF FATIGUE IN LONG-TERM SUR- 
VIVORS OF ALLOGENEIC STEM CELL TRANSPLANTATION: A PRELIMI- 
NARY ANALYSIS 
ICam; B.I; Xe~zocos'tas, A.2; ]g[ah, K. ~; Dev&s, G.~V[.~; Ii~'s, T.L.4; Lip- 
to11, J.H.4; Daly, A.4; Messlzev, H.A. 4 1. UMvevsity of Bilvni,gham, 
Bi*wdz~gham, United Kklgdom; 2. Lomlo~z Health Sciences Centre and 
the [hffversity of Weste~vz Ontario, TovoJzto, ON, C?mada; 3. Psycoso- 
ckd Oncology and Palliative Care Program~Princess Margaret Hospital 
a,d the Umversity of Toronto, Toronto, ON, Ca,ada; 4. P'dvzce.vs Mar- 
garet Hospital/U, iversity HeAlth Network and the Umvevsity ofToron- 
to, Toronto, ON, Canada. 
In allogeneic stem cell transplantation (alloSCT) populations, 
long-term fatigue is an important determinant of QOL that needs 
to be addressed. The  contribution of anemia to patients self- 
reported fatigue levels was examined. A questionnaire package was 
mailed to 290 recipients of blood or marrow allografts transplant- 
ed at our institution 1 to 7 years ago. The package included: 1) a 
100 mm Linear Analogue Self-Assessment (LASA) measure of 
energy, ability to perform daily activities, and overall QOL, 2) the 
anemia subscale of the FACT (FACT-An), which also includes 13 
items relating to fatigue (FACT-An fatigue subscale), and 3) a 
request for their most recent hemoglobin (Hb) level. An interim 
analysis was performed after 123 completed surveys (42%) had 
been returned. A total of 64% of the sample reported at least a 
mild level of fatigue, with 35 % reporting moderate to severe levels 
of fatigue on the FACT-An fatigue subscale. The FACT-An 
fatigue subscale scores were also standardized on a 1-100 scale 
(100 = no fatigue) and then compared to scores reported in studies 
of anemic cancer patients and healthy US individuals (1, 2). The 
mean score observed in our sample (63.3) was higher than the 
mean score observed in anemic cancer patients (56.7), but lower 
than the mean score obsmwed in healthy people (85.0). A total of 
26% of the sample met the criterion for anemia (Hb < 130 g/L for 
men and < 120 g/L for women). No significant correlations were 
found between Hb level and any of the fatigue measures. Other 
potential factors contributing to {:atigue were also examined. Sub- 
jects who were > 44 years old (median age) reported a higher level 
of fatigue than younger subjects on the LASA (energy level and 
daily activities) and the FACT-An fatigue subscale (p < 0.022). 
Level of fatigue was not related to the following potential risk fac- 
tors: gender, diagnosis, related vs. unrelated onor, GVHD, and 
time after SCT. Our findings suggest hat fatigue is a significant 
syanptom for the majority of long-term smwivors of alloSCT that 
appears to persist for years. However, anemia may not be a pri- 
mal T contributor to patients experience of fatigue. 1. Littlewood 
TJ et al. J Clin Oncol 2001; 19:2865-2874. 2. Nortier JWR et 
al.(abstract) Eur J Cancer 200i; 37:$35i (Supported by an unre- 
stricted grant from Ortho Biotech Canada). 
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POST-TRAUMATIC GROWTH: A LATE EFFECT OF STEM CELL 
TRANSPLANTATION 
Bishop, 3/LMd; Brady, 3/L ff.:; Beamno~zt, ff.L.e; Hahn, E.:; Celia, D.2; 
Amkykowski, 3/L S; Horowitz, ~/I.M.4; f4~1zgarcl, J.R. l 1. University of 
Florida, Gainesville, FL; 2. Ce,tev for O,tcomes Research a,d Ed, ca- 
tioJz, EvmzstoJ1 Northzvester, Healthcvre, Evanstozz, IL; 3. University of 
Kentztck3, College oj-'3/lediciTze, l,exilzgto~z, KI~" 4. b~te'l',atioTzal Bo,e 
Mazv'ozv Tivmplam ReghtJy(IBMTR)Zqutologo,s Blood and Ma'rrow 
Tra,lspla,t Regist' O, (ABMTR), Medical Colleg'e of T'}Zsco,silz, 3/lihvau- 
bee, ~q. 
Stem cell transplantation (SCq) prolongs life for many people 
and offers a cure for some. However, its late effects can signifi- 
cantly negatively impact the quality of life (QOL) of survivors. 
Often overlooked, positive quality of life outcomes are possible, as 
well, particularly in the area of psychological growth. A large, 
multi-center, cross-sectional study was conducted to characterize 
the QOL and quality of close relationships of long-term survivors 
of autologous and allogeneic SCT diagnosed with acute leukemia, 
chronic myelogenous leukemia, lymphoma, and breast cancer. 
Four hundred seventy seven survivors, 159 spouses, and 123 
healthy controls (matched on gender, age, marital stares, and edu- 
cation) were assessed as of June 2002. As part of this study, post 
traumatic growth was measured using the Post -Traumat ic  
Growth inventory (PTGI).  Survivors were mostly Caucasian 
(92 %), married (70%), of mean age 49 years (range = 21 - 77), and 
employed fulltime (51%). Mean years since transplant at assess- 
lnent was 6.9 (range = 1.8 - 22.6). Compared to spouses (M = 59.0) 
and controls (M = 57.8), smwivors reported more psychological 
growth (M = 66.4, p <.0001). In univariate analyses greater post- 
traumatic growth was associated with lower levels of education, 
and higher support group participation, as well as being female, 
having had an autologous transplant, having had less intensive 
prior therapy, and being diagnosed with breast cancer (all rela- 
tionships significant at p < .05) . Post-traumatic growth in sur- 
vivors was associated with greater use of certain coping strategies 
including positive reftaming (r = .33), emotional support (r = .35), 
instrumental support (r = .27), emotional processing (r = .27), and 
emotional expression (r = .21) (all values significant at p<.0001). In 
addition, psychological growth was associated with greater levels 
of spiritual well-being (r = .29, p < .0001). We conclude that psy- 
chological growth is possible post-transplant and further study of 
this positive late effect is warranted. 
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IN VIVO PURGING AND POST TRANSPLANT IMMUNOTHERAPY WITH 
RITUXIMAB PRODUCES DURABLE REMISSIONS IN PATIENTS WITH 
LOW GRADE AND MANTLE CELL LYMPHOMA 
Flim~, L ~;  Diehl, L.; Gray'err, E.; Carter-Brook&s, D.; Goody#h, A.; 
Loper, K.; JoTzes, R.ff.; Amb&der, R.F. Sidne~ Kilnmel Compvehelzsive 
Cancer Center atffohns HopteiJzs, Baltimore, MD. 
The efficacy of autologous tem cell transplantation for patients 
with lymphoma is complicated by residual disease remaining in 
the patient despite the high dose therapy and the re-introduction 
of neoplastic ells with the autologous graft. We are conducting 
trials of ritu~mab used during stem cell mobilization and as a post 
transplant adjuvant in an attempt o overcome both of these obsta- 
cles. Patients with NHL  received 375 mg/m 2 of rimximab day 1 of 
mobilization, followed by cyclophosphamide 2.5 gm/m 2 day 4, and 
either G-CSF or G CSF and GM-CSF starting" day 6 through 
subsequent stem cell collection. Later patients were CD34 select- 
ed if at least 5 X 10 c' CD 34 + cells/kg were collected. The prepar- 
ative regimen consisted of either Cy/TBI or Bu/Cy. The first 25 
patients received a single dose of ritnximab 375 mg/m 2 given post- 
transplant 7 days after plts reach 20,000. Subsequent patient 
received GM-CSF post-transplant with four weekly doses of ritux- 
imab. One hundred and twelve patients (75M:37F), median age 
52.5 (range 32-69)and 2 (range 1-7) prior therapies have started 
therapy. Diagnoses include 60 FCC, 24 mantle ceil, and 18 
SLL/CLL. At time of transplant, 37 patients were in CR, 72 in 
PR. Mobilization was successful in 89% of pts with a median 14.0 
x 106 CD+ 34 cells/kg. The median day ANC > 1000 was 12 (7- 
24) and unsupported platelet > 20, 000 was 9 (3-663). The purging 
results measured by lymphoma colony forming units and PCR 
before and after CD34 selection are displayed in the table. The 
median follow-up is 2 years. Kaplan-Meier estimates of the three 
year ~)verall and relapse flee survival are 91.4% [82.8%, 95.8%] 
and 84% [70.4%, 91.7%]respectively. Notable toxieities include 
increased incidence of cytopenias (predominantly neutropenia) 
. after engraftment and several ate infections ( aspergillus, atypical 
mycobacteriuin, pseudomonas). YVe conclude that rituximab used 
as an in vivo purging agent and post transplant adjuvant is well 
tolerated and produces durable remissions in patients with low 
grade and mantle cell NHL.  Evaluation of ilnmune reconstitution 
and late infections is ongoing. This approach will be tested in a 
randomized phase III intergroup trial in patients with diffuse large 
cell lymphoma. 
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iClonogenicAssay (-)7 PCR (-) 
Pre CD 34 selection I 55167 ~-  2//25 (84%) 
Post CD 34 selection ] 55/58 (95%) 17/i8 (94%) 
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THE USE OF EBV-SPECIFIC CYTOTOXIC T LYMPHOCYTES AS ADJU- 
VANT THERAPY POST STEM CELL TRANSPLANT FOR RELAPSED EBV- 
POSITIVE HODGKIN DISEASE 
Bollm'd, C.M.; Straathofi K.C.; Ha/s, H.; Lacaesta, RI; GJ-esik, M. l,i; 
Carrum, G.; Brenner', M.I<.; Rooney, C.M.; Heslop, H.E. Pediat~'ic 
He,~atology/Oneologv, Baylor College of MediciJ, e, Ho,tston, TX. 
Adoptive transfer of EBV specific cytotoxic T cells(CTL) has 
proved effective in preventing and treating immunogenic EBV 
lymphomas expressing type 3 EBV latency arising after hemopoi- 
etic stem cell transplantation(SCT). he tumor cells in around 
40% of cases of Hodgkin disease(HD) also contain the EBV 
genome although amore restricted array of EBV proteins includ- 
ing the subdominant EBV antigens LMP1 and LMP2 are 
expressed. We have evaluated the use of polyclonal EBV-CTL in 
patients with EBV+ HD with minimal residual disease post SCT. 
23 patients were referred to receive CTL post autologous SCT 
and 6 (26%) had EBV+ minors. 5 of these patients were treated 
with autologous CTL as adjuvant therapy post autologous SCT. 
Three received CTL at 2xI07/m -' and 2 received a CTL dose of 
1.2xl0S/m 2.An additional patient with EBV+ HD received an 
allogeneic SCT fi'om an unrelated onor and received one dose of 
2 x 10Vm-' donor-derived CTL. No immediate toxicity was 
observed post CTL. In tbe patient who received allogeneic CTL, 
the donor-derived CTL line showed 0.03% and 0.62% positivity 
for the A2 LMP2 tetramers and 2.49% for the LMP1 tetramer. 
No increase in the LMP2 tetramer population was seen post allo- 
geneic CTL but a 4-fold increase in the LMP1 tetramer popula- 
tion was demonstrated at 3 months. In the autologous CTL lines 
generated fi'onr 6 evaluble patients, an average of 1.61% (0.02- 
7.66%) of CD8 T cells were +ve for LMP2 which was similar to 
the frequency seen in CTL lines generated from normal donors. 
Using ELISPOT assay for yIFN secretion we saw a 1.5 to 2-fold 
increase in CTLp by 6 weeks in 3 patients. One patient had reso- 
lution of an abnormal gallium scan post CTL associated with 
reduced EBV DNA levels and a 4-fold increase in LMP2-specific 
CTL as detected by ELISPOT assay. Of the 5 patients who have 
received CTL after autologons SCT, 4 are well 12-30 mths post 
CTL. One patient died 3 mths post CTL with progressive disease. 
The patient who received allogeneic CTL remains welI 23 mths 
post SCT. In conclusion, EBV-specific CTL as adjuvant therapy 
post SCT appears afe at the lowest dose levels and anti-tumor 
effects have been observed. LMP2 or LMPI CTL are increased in 
the peripheral blood post CTL infusion and strategies to increase 
their frequency may result in a more specific cytotoxic response 
against EBV+ Hodgkin tumors. 
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REDUCED EARLY TRANSPLANT-RELATED MORTALITY FOLLOWING 
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) WITH FLUDARA- 
BINE-BASED, REDUCED-INTENSITY CONDITIONING FROM MATCHED 
RELATED AND UNRELATED DONORS IN ADVANCED HODGKIN'S DIS- 
EASE (HD) 
AncleJ'lini, P.; Aet, oloml, S.; Oleoroji, G.ff.; Giralt, S.; Ueno, N.; DoJ~a- 
to, 3/1.; AJ~del"sson, B.S.; Khmrri, L; Cbu*'iel, D.; Ippoliti, C.; l,}tA,e'rde, 
R.B.; C73amplin, R.E. Universi U of Texas 3/I.D. Anderson CatTeev Cen- 
ter, Blood and 3/[mwow 7)'ansplantation Depa~WHeTlt, HozIston, %~ 
Allogeneic SCT following a FDDP-based conditioning regimen 
was carried out in 25 patients with very advanced HD who failed 
multiple conventional treatments (median chemotherapy regi- 
mens: 5; range 2-9), radiation therapy (17/25) and a prior autolo- 
gous SCT (18/25). The median age was 30 years (18 56). Disease 
status at SCT was refractory relapse (n=8) and sensitive relapse 
(n=17). The median time to progression after autologous SCT 
was 9 months (2.5-52). The cell source was rhG-CSF-mobilized 
blood stem ceils from an HLA-identical sibling (n=12) or matched 
unrelated onor marrow (MUD; n=13). The conditioning regi- 
men was FDDP-cyclophosphamide)-_+ antithymocyte globulin 
(FC+_ATG) (n=13), and FDDP melphalan (FM140) (n=12). 8/12 
FM patients had a matched unrelated onor. Graft vs-host disease 
(GVHD) prophylaxis was tacrolimus and methotrexate. Myeloid 
recovery was prompt, with an absolute neutrophil count 
(ANC)>500/:L at day 11 (9-24). Median platelet recovery at 
20K/:L was at day i7 (9-50), with 7 patients never dropping below 
20K/:L after SCT, Chimerism and/or cytogenetic studies at day 
30-100 indicate 100% donor-derived engraftment in 12/12 
(100%) evaluable FM patients and in 7/12 (58%) evaluable 
FC_+ATG patients. Day 100 transplant-related mortality (TRT) 
was only 2/25 (8%) overall. It was 0/12 (0%) in sibling SCT recip- 
ients, and was 2/13 (15%) in MUD SCT recipients. Both 
deceased patients were MUD transplant recipients and one had 
been conditioned with FM140. Acute GVHD occurred in 13/23 
(56%) evaluable patients. Chronic GVHD was diagnosed in 11 
patients (extensive in 9). Nine patients have expired (8/9 received 
FC_+ATG), non-relapse mortality is 4/9 (44%) overa]l. Sixteen 
patients (64%) are alive (nine in remission) with a median follow- 
up of 10 months (1-51). Mlogeneic SCT from related and unrelat- 
ed donors with fludarabine-based, less intensive conditioning is
feasible in very high-risk, heavily pretreated HD. It yielded very 
promising results on engraftment, acute GVHD and, in particular, 
early TRT rates. The FM140 regimen is seemingly better suited 
for these patients. 
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A NOVEL STRATEGY FOR GENERATING LMPI SPECIFIC T CELLS UTI- 
LIZING ARTIFICIAL ANTIGEN PRESENTING CELLS 
Dozlbrovina, E.SJ; Lato~tc,~e*, j.s; Lee, 57; Raab-Trazlb, N.2; Pruner, 
E. 1; Sadelain, M.s; O'Reilly, R.J. I 1. M,w, ovkd Sloan-Kettering Ca*~cev 
CenteJ , New York, NIT; 2. University of North Carolina at Chapel Hill, 
Chapel Hill, NC. 
EBV contributes to the etiology of several human malignancies. 
However EBV+ nasopharyngeal carcinoma, EBV associated 
Hodgkins disease and leiomyosarcoma, express only the poorly 
immunogenic EBV antigens EBNAI, LMP 1 and LMP2. To gener- 
ate LMP1 specific CTL reactive against HLA-A0201+ EBV+ 
tumors, we used 3T3 cells genetically modified to express ttLA- 
A0201, beta2-microglobulin, the human co-stimulatory molecules 
BT.I, ICAM-1, LFA-I and the HLA-A0201 binding LMP1 peptide 
(YLLEMLWRL)  as artificial antigen presenting cells (AAPC) to 
stimulate T cells isolated from 9 HLA A0201+normaI donors. 
Control cultures were generated fi'om the same individuals against 
autologous EBV BLCL and against AAPCs expressing an Influenza 
matrix peptide rather than LMPI. LMP1 specific CDS+ T cells 
were quantitated with HLA-A0201-LMPI.1 tetramers; their spe- 
cific cytotoxicity was assessed by a standard 51Cr release assays. 
After 12 days, 8-17% of T ceils sensitized with HLA-A2-LMPI.1 
AAPC were tetramer positive and exhibited strong LMP1 specific 
HLA-A0201 restricted cytotoxicity (32-65%) against autologous 
EBV BLCLs. The specificity of cytoto~c responses against other 
EBV* A0201+ targets was confirmed by analysis of the LMP1 
sequence e~vpressed and was proportional to the level of LMP1 pro- 
tein detected in the target cells by intracellular immunostaining and 
FACS analysis. These T ceils were not reactive against K562, autol- 
ogous or HLA-A2+ PHA blasts, HLA mismatched EBV BLCL or 
mismatched LMPI pulsed targets. They did kill HLA-A0201+ 
EBV negative targets pulsed with LMP1 peptide. Strikingly, these 
CTL were highIy cytotoxic against an HLA-A0201 +EBV- leukemia 
transduced to express LMP1 and an EBV+ HLA-A0201+ nasopha- 
ryngeal carcinoma cell line. Such LMP1 reactive CTLs were not 
detected among T cells sensitized against autologous EBV BLCL. 
Evahiations of these T cells after adoptive transfer in xenografted 
SCID mice are in progress. These results indicate that AAPCs 
expressing LMP1 regularly stimulate the generation of LMP1 spe 
cific CTLs. Such cells could be used for adoptive immunotherapy 
of LMP1 positive malignancies which do not express immunogcnic 
EBV antigens. * this author equalIy contributed 
BB&MT 71 
